Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : RVNC save search
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.17%
H: 0.17%
C: -1.9%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -2.01%
H: 1.37%
C: -5.92%
daxxify neurology meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 17:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.0%
H: 0.08%
C: -1.83%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -11.6%
H: 3.89%
C: -1.62%
million offering
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.15%
H: 0.76%
C: 0.3%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.18%
H: 0.72%
C: -2.72%
year financial results
Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05 (Crawled : 11:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.12%
H: 3.45%
C: 3.4%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -2.42%
H: 1.05%
C: -2.67%
report cell global therapeutics market
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.42%
H: 1.75%
C: 1.28%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 1.59%
H: 4.11%
C: 0.78%
conference
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Published: 2024-01-08 (Crawled : 14:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.83%
H: 0.72%
C: -1.43%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -13.17%
H: 3.45%
C: -2.76%
year financial
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Published: 2023-11-01 (Crawled : 13:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.45%
H: 0.96%
C: 0.68%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -0.63%
H: 1.66%
C: 1.15%
financial results
Global Facial Injectable Market Analysis Report 2023-2028: New Product Launches, Increased Male Aesthetics, and Emerging Markets Driving Growth
Published: 2023-09-06 (Crawled : 10:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -0.46%
H: 1.38%
C: -2.87%
EOLS | $11.48 -1.88% -1.92% 260K
|
Health Technology
|
| O: 0.41%
H: 0.92%
C: -0.1%
report global growth market
Revance to Host Investor Day on September 19, 2023
Published: 2023-08-22 (Crawled : 14:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.18%
H: 0.45%
C: -0.62%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.28%
H: 2.33%
C: 1.65%
day
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify fda treatment injection
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Published: 2023-08-01 (Crawled : 13:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.19%
H: 0.29%
C: -2.76%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
financial results
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Published: 2023-05-02 (Crawled : 12:20) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.21%
H: 0.21%
C: -2.36%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.65%
H: 2.62%
C: 1.97%
financial results
Revance to Participate in Upcoming Investor Conferences - March 7, 2023
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.09%
H: 0.18%
C: -1.29%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.36%
H: 0.69%
C: -0.6%
Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR
Published: 2023-03-01 (Crawled : 04:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.29%
H: 0.0%
C: -0.13%
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: 0.64%
H: 0.85%
C: -1.6%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.74%
H: 1.85%
C: 1.64%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -3.46%
H: 3.43%
C: -3.73%
global report market
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -1.13%
H: 3.69%
C: -1.58%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.79%
H: 3.84%
C: 2.06%
conference
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.44%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 0.48%
H: 4.73%
C: 2.5%
daxxify treatment meeting association injection
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-01-09 (Crawled : 19:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.17%
H: 0.58%
C: -0.91%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 15.12%
H: 34.86%
C: 34.07%
daxxify commercial year financial update results
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
Published: 2022-11-22 (Crawled : 14:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -1.35%
H: 1.46%
C: 1.19%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -0.14%
H: 3.44%
C: 2.76%
conference
Nanostics Announces New Member of Board of Directors
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -1.81%
H: 0.88%
C: -3.34%
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
Published: 2022-11-04 (Crawled : 13:20) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: 1.44%
H: 0.0%
C: -2.93%
aesthetic injection
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.